Bracco Imaging ‘Ups’ its Precision Medicine Game with Blue Earth Diagnostics
Bracco Imaging is set to acquire Blue Earth Diagnostics for about $450 million.
Upon closing of the transaction, Burlington, the MA-based company will be a subsidiary of Bracco Imaging, led by its current leadership team. Milan, Italy-based Bracco Imaging said Blue Earth Diagnostics will retain the well-established brand name.
âBlue Earth Diagnosticsâ innovative products and pipeline will significantly enhance Bracco Imagingâs portfolio in precision medicine and personalized diagnostics, while expanding our range of nuclear oncology imaging solutions in the Urology segment and other specialties,â said Fulvio Renoldi Bracco, CEO of Bracco Imaging, said in a release. âWe are thrilled to welcome to Bracco this world class team with exceptional product development and commercialization expertise.â
Blue Earth Diagnosticsâ first commercialized product, Axumin (fluciclovine F 18) injection is a novel molecular imaging agent approved in the U.S. and the European Union for use in PET imaging for men with suspected recurrent prostate cancer. 18F-Fluciclovine has a broad range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating the molecule for utility in other cancers, including in neuro-oncology.
Blue Earth Diagnostics has had significant progress with its prostate cancer detection offerings. Last year, the company pres...
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Imaging IVD Source Type: news
More News: Brain | Cancer | Cancer & Oncology | CT Scan | Italy Health | Medical Devices | Mergers and Aquisitions | Neurology | PET Scan | Prostate Cancer | Urology & Nephrology